WCLC 2023 | The future of I-SABR in lung cancer

Joe Chang, MD, PhD, The University of Texas MD Anderson Cancer Centre, Houston, Texas, discusses the future of immunotherapy alongside stereotactic ablative radiotherapy (I-SABR) in the treatment of lung cancer. A current goal is to use radiomic biomarkers to investigate which populations of patients with lung cancer can benefit from I-SABR. Prof. Chang suggests that I-SABR can be used for advanced stage lung cancers in the future and the strategy has been shown to improve progression-free survival in multiple randomised pilot studies. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.